Mouse models of neurological disorders-A comparison of heritable and acquired traits

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 10, 2010, Pages 785-795

  Harper, Alex ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Acquired trai; Disease; Inherited trait; Mouse model; Neurology

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; MICROTUBULE ASSOCIATED PROTEIN; OXIDOPAMINE; TAU PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ANIMAL MODEL; BRAIN ISCHEMIA; ENCEPHALITIS; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRAIT; HUMAN; HUNTINGTON CHOREA; LESCH NYHAN SYNDROME; MULTIPLE SCLEROSIS; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SCHIZOPHRENIA; TARDIVE DYSKINESIA; ANIMAL; DISEASE MODEL; GENETIC PREDISPOSITION; GENETICS; MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; NERVOUS SYSTEM DISEASES;

MUS;

EID: 77956059872     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.05.009     Document Type: Review

References (115)

1. Alzheimer A. Über einen eigenartigen, schweren Erkrankungsprozess der Hirnrinde. Neurol Zbl 1906, 25:1134.
2. Huntington G. On chorea. Med Surg Rep 1872, 26:317.
3. Parkinson J. An essay on the shaking palsy. J. Neuropsychiatry Clin. Neurosci. 2002, 14:223.
4. Frazer K.A., Eskin E., Kang H.M., Bogue M.A., Hinds D.A., Beilharz E.J., Gupta R.V., Montgomery J., Morenzoni M.M., Nilsen G.B., Pethiyagoda C.L., Stuve L.L., Johnson F.M., Daly M.J., Wade C.M., Cox D.R. A sequence-based variation map of 8.27 million SNPs in inbred mouse strains. Nature 2007, 448:1050.
5. Oosthoek S. The mouse man of Maine. New Sci. 2009, 201:54.
6. Waterston R.H., Lindblad-Toh K., Birney E., Rogers J., Abril J.F., Agarwal P., Agarwala R., Ainscough R., Alexandersson M., An P., Antonarakis S.E., Attwood J., Baertsch R., Bailey J., Barlow K., Beck S., Berry E., Birren B., Bloom T., Bork P., Botcherby M., Bray N., Brent M.R., Brown D.G., Brown S.D. Initial sequencing and comparative analysis of the mouse genome. Nature 2002, 420:520. [Review].
7. Letts V.A., Felix R., Biddlecome G.H., Arikkath J., Mahaffey C.L., Valenzuela A., Bartlett F.S., Mori Y., Campbell K.P., Frankel W.N. The mouse stargazer gene encodes a neuronal Ca2+-channel gamma subunit. Nat. Genet. 1998, 19:340.
8. Morrissette D.A., Parachikova A., Green K.N., LaFerla F.M. Relevance of transgenic mouse models to human Alzheimer disease. J. Biol. Chem. 2009, 284:6033. [Review].
9. Hogan B., Beddington R., Costantini F., Lacey E. Manipulating the Mouse Embryo: A Laboratory Manual 1994.
10. Acevedo-Arozena A., Wells S., Potter P., Kelly M., Cox R.D., Brown S.D.M. ENU mutagenesis, a way forward to understand gene function. Annu. Rev. Genomics Hum. Genet. 2008, 9:49. [Review].
11. http: and A Transcriptome Database for Astrocytes, Neurons, and Oligodendrocytes, 2010. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9566.
12. http: and MyMouse. Org - What's Wrong With My Mouse?, 2010. http://ww.mymouse.org/index.html.
13. http: and Background on Mouse As a Model Organism, 2010. http://www.genome.gov/10005834.
14. http: and Alzheimer Research Forum - Research Models, 2010. http://www.alzforum.org/res/com/tra/default.asp.
15. http: and The Jackson Laboratory, 2010. http://jaxmice.jax.org/findmice/index.html.
16. Duyckaerts C., Potier M.C., Delatour B. Alzheimer disease models and human neuropathology: similarities and differences [Review]. Acta Neuropathol. 2008, 115:5.
17. Lim K.L., Ng C.H. Genetic models of Parkinson disease. Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease 2009, 1792:604.
18. Walker F.O. Huntington's disease. Lancet 2007, 369:218.
19. Frank S., Clavaguera F., Tolnay M. Tauopathy models and human neuropathology: similarities and differences. Acta Neuropathol. 2008, 115:39. [Review].
20. Julien J.P., Kriz J. Transgenic mouse models of amyotrophic lateral sclerosis. Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease 2006, 1762:1013.
21. Lodi R., Tonon C., Calabrese V., Schapira A.H.V. Friedreich's ataxia: From disease mechanisms to therapeutic interventions. Antioxid. Redox Signal. 2006, 8:438. [Review].
22. Willmann R., Possekel S., Dubach-Powell J., Meier T., Ruegg M.A. Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul. Disord. 2009, 19:241. [Review].
23. Wells T., Carter D.A. Genetic engineering of neural function in transgenic rodents: towards a comprehensive strategy?. J. Neurosci. Meth. 2001, 108:111.
24. Kokjohn T.A., Roher A.E. Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement. 2009, 5:340. [Review].
25. Howlett D.R., Richardson J.C. The pathology of APP transgenic mice: a model of Alzheimer's disease or simply overexpression of APP?. Histol. Histopathol. 2009, 24:83. [Review].
26. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagopian S., Johnsonwood K., Khan K., Lee M., Leibowitz P., Lieberburg I., Little S., Masliah E., McConlogue L., Montoyazavala M., Mucke L., Paganini L., Penniman E., Power M., Schenk D. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523.
27. German D.C., Yazdani U., Speciale S.G., Pasbakish P., Games D., Liang C.L. Cholinergic neuropathology in a mouse model of Alzheimer's disease. J. Comp. Neurol. 2003, 462:371.
28. Dodart J.C., Meziane H., Mathis C., Bales K.R., Paul S.M., Ungerer A. Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Behav. Neurosci. 1999, 113:982.
29. Chen G.Q., Chen K.S., Knox J., Inglis J., Bernard A., Martin S.J., Justice A., McConlogue L., Games D., Freedman S.B., Morris R.G.M. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000, 408:975.
30. Donovan M.H., Yazdani U., Norris R.D., Games D., German D.C., Eisch A.J. Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease. J. Comp. Neurol. 2006, 495:70.
31. Chen K.S., Masliah E., Grajeda H., Guido T., Huang J., Khan K., Motter R., Soriano F., Games D., Chen K.S., Masliah E., Grajeda H., Guido T., Huang J., Khan K., Motter R., Soriano F., Games D. Neurodegenerative Alzheimer-like pathology in PDAPP 717V->F transgenic mice. Prog. Brain Res. 1998, 117:327. [Review] [37 refs].
32. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184.
33. DeMattos R.B., Bales K.R., Parsadanian M., O'Dell M.A., Foss E.M., Paul S.M., Holtzman D.M. Plaque-associated disruption of CSF and plasma amyloid-beta (A beta) equilibrium in a mouse model of Alzheimer's disease. J. Neurochem. 2002, 81:229.
34. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. U. S. A. 2001, 98:8850.
35. Wight P.A., Duchala C.S., Shick H.E., Gudz T.I., Macklin W.B. Expression of a myelin proteolipid protein (Plp)-lacZ transgene is reduced in both the CNS and PNS of Plp(jp) mice. Neurochem. Res. 2007, 32:343.
36. Harrison S.M., Harper A.J., Hawkins J., Duddy G., Grau E., Pugh P.L., Winter P.H., Shilliam C.S., Hughes Z.A., Dawson L.A., Gonzalez M.I., Upton N., Pangalos M.N., Dingwall C. BACE1 (beta-secretase) transgenic neurochernical deficits ind knockout mice: identification of and behavioral changes. Mol. Cell. Neurosci. 2003, 24:646.
37. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K., Tsuda T., Mar L., Foncin J.F., Bruni A.C., Montesi M.P., Sorbi S., Rainero I., Pinessi L., Nee L., Chumakov I., Pollen D., Brookes A., Sanseau P., Polinsky R.J., Wasco W., Stgeorgehyslop P.H. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995, 375:754.
38. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Pereztur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., Younkin S. Increased amyloid-beta-42(43) in brains of mice expressing mutant presenilin 1. Nature 1996, 383:710.
39. Howlett D.R., Richardson J.C., Austin A., Parsons A.A., Bate S.T., Davies D.C., Gonzalez M.I. Cognitive correlates of A beta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res. 2004, 1017:130.
40. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van E.L., Berry R., Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 2006, 26:10129.
41. Hutton M., Lewis J., Dickson D., Yen S.H., McGowan E. Analysis of tauopathies with transgenic mice. Trends Mol. Med. 2001, 7:467. [Review].
42. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A[beta] and synaptic dysfunction. Neuron 2003, 39:409.
43. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493.
44. Ciarnei A., Morton A.J. Rigidity in social and emotional memory in the R6/2 mouse model of Huntington's disease. Neurobiol. Learn. Mem. 2008, 89:533.
45. Gibson H.E., Reim K., Brose N., Morton A.J., Jones S. A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse. Eur. J. Neurosci. 2005, 22:1701.
46. Sun Y., Chen X., Xiao D., Sun Y., Chen X., Xiao D. Tetracycline-inducible expression systems: new strategies and practices in the transgenic mouse modeling. Acta Biochimica Et Biophysica Sinica 2007, 39:235. [Review] [64 refs].
47. Mallo M. Controlled gene activation and inactivation in the mouse. Front. Biosci. 2006, 11:313. [Review].
48. Zhu Z., Ma B., Homer R.J., Zheng T., Elias J.A. Use of the tetracycline-controlled transcriptional silencer (tTS) to eliminate transgene leak in inducible overexpression transgenic mice. J. Biol. Chem. 2001, 276:25222.
49. SantaCruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., DeTure M., Ramsden M., McGowan E., Forster C., Yue M., Orne J., Janus C., Mariash A., Kuskowski M., Hyman B., Hutton M., Ashe K.H. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476.
50. Gossen M., Freundlieb S., Bender G., Muller G., Hillen W., Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995, 268:1766.
51. Mayford M., Bach M.E., Huang Y.Y., Wang L., Hawkins R.D., Kandel E.R. Control of memory formation through regulated expression of a CamKII transgene. Science 1996, 274:1678.
52. Ramsden M., Kotilinek L., Forster C., Paulson J., McGowan E., SantaCruz K., Guimaraes A., Yue M., Lewis J., Carlson G., Hutton M., Ashe K.H. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J. Neurosci. 2005, 25:10637.
53. Spires T.L., Orne J.D., SantaCruz K., Pitstick R., Carlson G.A., Ashe K.H., Hyman B.T. Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am. J. Pathol. 2006, 168:1598.
54. Berger Z., Roder H., Hanna A., Carlson A., Rangachari V., Yue M., Wszolek Z., Ashe K., Knight J., Dickson D., Andorfer C., Rosenberry T.L., Lewis J., Hutton M., Janus C. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J. Neurosci. 2007, 27:3650.
55. Chikama T., Hayashi Y., Liu C.Y., Terai N., Terai K., Kao C.W.C., Wang L., Hayashi M., Nishida T., Sanford P., Doestchman T., Kao W.W.Y. Characterization of tetracycline-inducible bitransgenic Krt12rtTA/+/tet-O-LacZ mice. Invest. Ophthalmol. Vis. Sci. 2005, 46:1966.
56. Shen J., Bronson R.T., Chen D.F., Xia W., Selkoe D.J., Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell 1997, 89:629.
57. Yu H., Saura C.A., Choi S.Y., Sun L.D., Yang X., Handler M., Kawarabayashi T., Younkin L., Fedeles B., Wilson M.A., Younkin S., Kandel E.R., Kirkwood A., Shen J. APP processing and synaptic plasticity in Presenilin-1 conditional knockout mice. Neuron 2001, 31:713.
58. Reaume A.G., Howland D.S., Trusko S.P., Savage M.J., Lang D.M., Greenberg B.D., Siman R., Scott R.W. Enhanced amyloidogenic processing of the beta-Amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a humanized A-beta sequence. J. Biol. Chem. 1996, 271:23380.
59. Tong Y., Pisani A., Martella G., Karouani M., Yamaguchi H., Pothos E.N., Shen J. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl Acad. Sci. 2009, 106:14622.
60. Li Y., Liu W., Oo T.F., Wang L., Tang Y., Jackson-Lewis V., Zhou C., Geghman K., Bogdanov M., Przedborski S., Beal M.F., Burke R.E., Li C. Mutant LRRK2-R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 2009, 12:826.
61. Koss D.J., Stoppelkamp S., Riedel G., Platt B. The first third-generation Alzheimer mouse, PLB1: Tissue analyses and histology. Alzheimers Dement. 2009, 5:433.
62. Franklin K., Paxinos G. The mouse brain in stereotaxic coordinates 2007, Academic Press.
63. Brill D. Mouse brain map is complete. Nature 2006, 443:380.
64. Coyle J.T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993, 262:689.
65. Dingledine R., Borges K., Bowie D., Traynelis S.F. The glutamate receptor ion channels. Pharmacol. Rev. 1999, 51:7. [Review].
66. Myers S.J., Dingledine R., Borges K. Genetic regulation of glutamate receptor ion channels. Annu. Rev. Pharmacol. Toxicol. 1999, 39:221. [Review].
67. Bubenikova-Valesova V., Horacek J., Vrajova M., Hoschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neuroscience & Biobehavioral Reviews 2008, 32:1014. [Review].
68. Beraki S. R.az-Heijtz, F. Tai, and S.O. Ogren, Effects of repeated treatment of phencyclidine on cognition and gene expression in C57BL/6 mice. Int. J. Neuropsychopharmacol. 2009, 12:243.
69. Savioz A., Leuba G., Vallet P.G., Walzer C. Contribution of neural networks to Alzheimer disease's progression. Brain Res. Bull. 2009, 80:309. [Review].
70. Lister J.P., Barnes C.A. Neurobiological changes in the hippocampus during normative aging. Arch. Neurol. 2009, 66:829. [Review].
71. Logue S.F., Paylor R., Wehner J.M., Logue S.F., Paylor R., Wehner J.M. Hippocampal lesions cause learning deficits in inbred mice in the Morris water maze and conditioned-fear task. Behav. Neurosci. 1997, 111:104.
72. Deacon R.M.J., Bannerman D.M., Kirby B.P., Croucher A., Rawlins J.N. Effects of cytotoxic hippocampal lesions in mice on a cognitive test battery. Behav. Brain Res. 2002, 133:57.
73. Nakazawa K., McHugh T.J., Wilson M.A., Tonegawa S. NMDA receptors, place cells and hippocampal spatial memory. Nat. Rev. Neurosci. 2004, 5:361. [Review].
74. Yaimin G. NMDA receptor-dependent signaling pathways that underlie Amyloid beta-protein disruption of LTP in the hippocampus. J. Neurosci. Res. 2009, 87:1729. [Review].
75. Zhao X., Rosenke R., Kronemann D., Brim B., Das S.R., Dunah A.W., Magnusson K.R. The effects of aging on N-methyl-d-aspartate receptor subunits in the synaptic membrane and relationships to long-term spatial memory. Neuroscience 2009, 162:933.
76. Gilmour G., Pioli E.Y., Dix S.L., Smith J.W., Conway M.W., Jones W.T., Loomis S., Mason R., Shahabi S., Tricklebank M.D., Gilmour G., Pioli E.Y., Dix S.L., Smith J.W., Conway M.W., Jones W.T., Loomis S., Mason R., Shahabi S., Tricklebank M.D. Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia. Psychopharmacology 2009, 205:203.
77. Fox G.B., Fan L., LeVasseur R.A., Faden A.I. Effect of traumatic brain injury on mouse spatial and nonspatial learning in the Barnes circular maze. J. Neurotrauma 1998, 15:1037.
78. Barone F.C., Kilgore K.S. Role of inflammation and cellular stress in brain injury and central nervous system diseases. Clin. Neurosci. Res. 2006, 6:329. [Review].
79. I.L. Campbell, M.J. Hofer, and A. Pagenstecher, Transgenic models for cytokine-induced neurological disease, Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease In Press, Corrected Proof (2009).
80. Moisse K., Welch I., Hill T., Volkening K., Strong M.J. Transient middle cerebral artery occlusion induces microglial priming in the lumbar spinal cord: a novel model of neuroinflammation-art. no. 29. J. Neuroinflammation 2008, 5:29.
81. Pluta R., Ulamek M., Jablonski M. Alzheimer's mechanisms in ischemic brain degeneration 2009, [Review], Anatomical Record, Hoboken, NJ, 1863.
82. Stromnes I.M., Goverman J.M. Active induction of experimental allergic encephalomyelitis. Nat. Protoc. 2006, 1:1810. [Review].
83. Kuerten S., Angelov D.N. Comparing the CNS morphology and immunobiology of different EAE models in C57BL/6 mice-a step towards understanding the complexity of multiple sclerosis. Ann. Anat. 2008, 190:1. [Review].
84. Pollak Y., Ovadia H., Goshen I., Gurevich R., Monsa K., Avitsur R., Yirmiya R. Behavioral aspects of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2000, 104:31.
85. Deumens R., Blokland A., Prickaerts J., Deumens R., Blokland A., Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 2002, 175:303. [Review] [70 refs].
86. Im H.I., Joo W.S., Nam E., Lee E.S., Hwang Y.J., Kim Y.S. Baicalein prevents 6-hydroxydopamine-induced dopaminergic dysfunction and lipid peroxidation in mice. J. Pharmacol. Sci. 2005, 98:185.
87. Metz G.A., Tse A., Ballermann M., Smith L.K., Fouad K. The unilateral 6-OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis. Eur. J. Neurosci. 2005, 22:735.
88. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2007, 2:141.
89. Neisewander J.L., Lucki I., McGonigle P., Neisewander J.L., Lucki I., McGonigle P. Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment. Brain Res. 1991, 558:27.
90. Carvalho R.C., Silva R.H., Abilio V.C., Barbosa P.N., Frussa R. Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice. Brain Res. Bull. 2003, 60:115.
91. Castro J.P.M.V., Frussa-Filho R., Fukushiro D.F., Silva R.H., Medrano W.A., Ribeiro R.D., Abilio V.C. Effects of baclofen on reserpine-induced vacuous chewing movements in mice. Brain Res. Bull. 2006, 68:436.
92. Brouillet E., Conde F., Beal M.F., Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 1999, 59:427. [Review].
93. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 1993, 13:4181.
94. Acevedo-Torres K., Berrios L., Rosario N., Dufault V., Skatchkov S., Eaton M.J., Torres-Ramos C.A., Ayala-Torres S. Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease. DNA Repair 2009, 8:126.
95. Damiano M., Galvan L., Deglon N., Brouillet E. Mitochondria in Huntington's disease. Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease 2010, 1802:52.
96. Krivoy A., Fischel T., Weizman A. The possible involvement of metabotropic glutamate receptors in schizophrenia. Eur. Neuropsychopharmacol. 2008, 18:395. [Review].
97. Levin E.D., Petro A., Caldwell D.P. Nicotine and clozapine actions on pre-pulse inhibition deficits caused by N-methyl-d-aspartate (NMDA) glutamatergic receptor blockade. Prog. Neuro Psychopharmacol. Biol. Psychiatry 2005, 29:581. [Review].
98. Ellenbroek B.A., Cools A.R. Animal models of psychotic disturbances. Advances in the neurobiology of schizophrenia, Wiley series on clinical and neurobiological advances in psychiatry 1995, 89-109. John Wiley & Sons, Oxford, England. J.A. Den Boer, H.G.M. Westenberg, H.M. van Praag (Eds.).
99. Ellenbroek B.A., Cools A.R. The neurodevelopment hypothesis of schizophrenia-clinical evidence and animal models. Neurosci. Res. Commun. 1998, 22:127. [Review].
100. Fabricius K., Wortwein G., Pakkenberg B., Fabricius K., Wortwein G., Pakkenberg B. The impact of maternal separation on adult mouse behaviour and on the total neuron number in the mouse hippocampus. Brain Struct. Funct. 2008, 212:403.
101. Fire A., Xu S.Q., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806.
102. Lim L.P., Glasner M.E., Yekta S., Burge C.B., Bartel D.P. Vertebrate MicroRNA genes. Science 2003, 299:1540.
103. Kocerha J., Kauppinen S., Wahlestedt C., Kocerha J., Kauppinen S., Wahlestedt C. microRNAs in CNS disorders. Neuromolecular Med. 2009, 11:162.
104. Royle S.J., Collins F.C., Rupniak H.T., Barnes J.C., Anderson R. Behavioural analysis and susceptibility to CNS injury of four inbred strains of mice. Brain Res. 1999, 816:337.
105. Taketo M., Schroeder A.C., Mobraaten L.E., Gunning K.B., Hanten G., Fox R.R., Roderick T.H., Stewart C.L., Lilly F., Hansen C.T., Taketo M., Schroeder A.C., Mobraaten L.E., Gunning K.B., Hanten G., Fox R.R., Roderick T.H., Stewart C.L., Lilly F., Hansen C.T. FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc. Natl Acad. Sci. U. S. A. 1991, 88:2065.
106. Sullivan K.A., Hayes J.M., Wiggin T.D., Backus C., Su Oh S., Lentz S.I., Brosius F., Feldman E.L. Mouse models of diabetic neuropathy. Neurobiol. Dis. 2007, 28:276.
107. Barone F.C., Knudsen D.J., Nelson A.H., Feuerstein G.Z., Willette R.N. Mouse strain differences in susceptibility to cerebral ischemia are related to cerebral vascular anatomy. J. Cereb. Blood Flow Metab. 1993, 13:683.
108. Rogers D.C., Fisher E.M., Brown S.D., Peters J., Hunter A.J., Martin J.E. Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm. Genome 1997, 8:711.
109. Rogers D.C., Jones D.N., Nelson P.R., Jones C.M., Quilter C.A., Robinson T.L., Hagan J.J. Use of SHIRPA and discriminant analysis to characterise marked differences in the behavioural phenotype of six inbred mouse strains. Behav. Brain Res. 1999, 105:207.
110. Fray M.D., Pickard A.R., Harrison M., Cheeseman M.T. Upgrading mouse health and welfare: direct benefits of a large-scale rederivation programme. Lab Anim. 2008, 42:127.
111. Smith A.L., Corrow D.J., Smith A.L., Corrow D.J. Modifications to husbandry and housing conditions of laboratory rodents for improved well-being. ILAR J. 2005, 46:140. [Review] [48 refs].
112. Davis R.R., Kozel P., Erway L.C., Davis R.R., Kozel P., Erway L.C. Genetic influences in individual susceptibility to noise: a review. Noise Health 2003, 5:19. [Review] [19 refs].
113. Pietropaolo S., Singer P., Feldon J., Yee B.K. The postweaning social isolation in C57BL/6 mice: preferential vulnerability in the male sex. Psychopharmacology 2008, 197:613. [Review].
114. Nicholson A., Malcolm R.D., Russ P.L., Cough K., Touma C., Palme R., Wiles M.V. The response of C57BL/6J and BALB/cJ mice to increased housing density. Journal of the American Association for Laboratory Animal Science: JAALAS 2009, 48:740.
115. Lynch M. Design and analysis of experiments on random drift and inbreeding depression. Genetics 1988, 120:791.